MiMedx Group (NASDAQ:MDXG) Issues Quarterly Earnings Results

Key Points

• MiMedx reported adjusted EPS of ($0.05), beating estimates by $0.02, but revenue missed at $58.99 million as Q1 net sales fell ~33% YoY with surgical sales up 13% while wound sales plunged ~60%.
• Management has implemented ~$40 million of annualized cost savings, ended the quarter with roughly $142 million in cash, authorized a $100 million buyback, and expects sequential recovery with profitability beginning in Q3 and full‑year adjusted EBITDA roughly break‑even on guidance of $260–290 million in revenue.
• The stock traded down ~9% after the release, the company has a market cap near $459 million, and analysts hold a consensus "Moderate Buy" with an average price target of about $8.67.

MiMedx Group (NASDAQ:MDXG - Get Free Report) released its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02, FiscalAI reports. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The firm had revenue of $58.99 million for the quarter, compared to analysts' expectations of $69.47 million.

Here are the key takeaways from MiMedx Group's conference call:

• The company reported Q1 net sales of $59 million (down 33% YoY), with surgical +13% and wound -60%, an adjusted EBITDA loss of $12 million, and roughly $142 million net cash at quarter end.
• MiMedx says the steep wound-care decline stems from CMS reimbursement changes (ASP→fixed-price cap), the abrupt non‑implementation of LCDs, and a problematic WISeR prior‑authorization rollout that has severely slowed claims processing and provider utilization.
• The surgical franchise remains the growth engine—Q1 surgical sales grew 13%, the business is up ~50% over three years, and the company launched new products (AmnioFix Thyroid Shield, G4Derm Plus, HydroLix) while completing the EPIEFFECT RCT and PRP market release.
• Management implemented ~$40 million of annualized cost saves (including a ~15% workforce reduction and a ~$4 million Q2 charge) and expects sequential recovery to reach profitability starting in Q3 with full‑year adjusted EBITDA roughly break‑even and guidance of $260–290 million in revenue.
• Balance sheet and capital actions: MiMedx emphasizes a strong cash position and has a board‑authorized $100 million share repurchase program while retaining flexibility for M&A and opportunistic buybacks.

MiMedx Group Trading Down 9.1%

MiMedx Group stock opened at $3.09 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. MiMedx Group has a one year low of $3.03 and a one year high of $7.99. The stock has a market capitalization of $459.07 million, a PE ratio of 9.66 and a beta of 1.65. The business's fifty day moving average is $4.16 and its 200 day moving average is $5.65.

Hedge Funds Weigh In On MiMedx Group

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kemnay Advisory Services Inc. purchased a new stake in shares of MiMedx Group during the 4th quarter valued at about $48,000. Headlands Technologies LLC purchased a new position in shares of MiMedx Group during the second quarter valued at approximately $72,000. Jain Global LLC purchased a new stake in MiMedx Group in the fourth quarter worth approximately $73,000. Virtu Financial LLC purchased a new stake in MiMedx Group in the fourth quarter worth approximately $78,000. Finally, Osaic Holdings Inc. grew its position in MiMedx Group by 57.2% in the 2nd quarter. Osaic Holdings Inc. now owns 12,943 shares of the company's stock worth $79,000 after purchasing an additional 4,708 shares during the period. Institutional investors own 79.15% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MDXG. UBS Group set a $10.00 price target on shares of MiMedx Group in a research note on Monday, February 23rd. Citigroup began coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They set a "market outperform" rating for the company. Citizens Jmp reaffirmed a "market outperform" rating and issued a $7.00 target price (down from $10.00) on shares of MiMedx Group in a report on Monday, April 20th. Wall Street Zen downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. Finally, Lake Street Capital cut their price target on shares of MiMedx Group from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 20th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, MiMedx Group has a consensus rating of "Moderate Buy" and an average price target of $8.67.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.